Publicaciones en colaboración con investigadores/as de University Hospital Heidelberg (5)

2024

  1. Best original research presented at the 25th European Congress on Gynaecological Oncology: Best of ESGO 2024

    International Journal of Gynecological Cancer, Vol. 34, Núm. 9, pp. 1324-1333

2020

  1. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    The Lancet Oncology, Vol. 21, Núm. 4, pp. 519-530

2019

  1. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2416-2428

2016

  1. Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-Expressing platinum-resistant ovarian Cancer (PENELOPE)

    Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2516-2525

  2. Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial

    International Journal of Gynecological Cancer, Vol. 26, Núm. 5, pp. 898-905